Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00616642 · ClinicalTrials.gov registry record · Phase 2
Rosiglitazone in Treating Patients With Pituitary Tumors
A Phase 2 study, sponsored by Jonsson Comprehensive Cancer Center.
- Terminated
- Registry status
- Phase 2
- Development phase
- 1
- Enrollment target
NCT00616642: Clinical Trial Phase 2 study, sponsored by Jonsson Comprehensive Cancer Center.
NCT00616642 is a Phase 2 study that was terminated before completion, run by Jonsson Comprehensive Cancer Center. The registered enrollment target is 1 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (99% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00616642, a Phase 2 study, was terminated before completion, sponsored by Jonsson Comprehensive Cancer Center.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 1 participants
- Enrollment target
Study Summary
RATIONALE: Rosiglitazone may help pituitary adenoma cells become more like normal cells, and grow and spread more slowly. PURPOSE: This phase II trial is studying how well rosiglitazone works in treating patients with newly diagnosed or residual or recurrent pituitary adenoma.
Primary Outcome
Reduction in pituitary tumor volume by over 50% as assessed by MRI to measurements made at baseline.
Interventions
- DRUG rosiglitazone maleate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2006-10 |
| Est. Completion | 2010-11 |
| Phase | Phase 2 |
Why NCT00616642 stopped before completion
NCT00616642 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 1 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (99% lower).
The record links to 0 conditions, and to 1 intervention - of which rosiglitazone maleate is the first listed.
NCT00616642 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00616642 about?
NCT00616642 is a clinical study titled "Rosiglitazone in Treating Patients With Pituitary Tumors". RATIONALE: Rosiglitazone may help pituitary adenoma cells become more like normal cells, and grow and spread more slowly. PURPOSE: This phase II trial is studying how well rosiglitazone works in treating patients with newly diagnosed or residual or recurrent pituitary adenoma.
What is the current status of trial NCT00616642?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 1 participants. The study started on 2006-10. Estimated completion is 2010-11.
What interventions are being tested in trial NCT00616642?
The interventions under investigation include: rosiglitazone maleate (DRUG).
Who is sponsoring clinical trial NCT00616642?
This trial is sponsored by Jonsson Comprehensive Cancer Center, which has 321 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00616642's enrollment target sits among peer trials
1 2001st of 2000 the lowest of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia